HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Englerin A Rewires Phosphosignaling via Hsp27 Hyperphosphorylation to Induce Cytotoxicity in Renal Cancer Cells.

Abstract
Englerin A (EA) is a small-molecule natural product with selective cytotoxicity against renal cancer cells. EA has been shown to induce apoptosis and cell death through cell-cycle arrest and/or insulin signaling pathways. However, its biological mode of action or targets in renal cancer remains enigmatic. In this study, we employed advanced mass spectrometry-based phosphoproteomics approaches to identify EA's functional roles in renal cancer. We identified 10,940 phosphorylation sites, of which 706 sites exhibited EA-dependent phosphorylation changes. Integrated analysis of motifs and interaction networks suggested activation of stress-activated kinases including p38 upon EA treatment. Of note, a downstream target of p38, Hsp27, was found to be hyperphosphorylated on multiple sites upon EA treatment. Among these, a novel site Ser65 on Hsp27, which was further validated by targeted proteomics, was shown to be crucial for EA-induced cytotoxicity in renal cancer cells. Taken together, these data reveal the complex signaling cascade that is induced upon EA treatment and importantly provide insights into its effects on downstream molecular signaling.
AuthorsSuat Peng Neo, Asfa Alli-Shaik, Sheena Wee, Zijie Lim, Jayantha Gunaratne
JournalJournal of proteome research (J Proteome Res) Vol. 21 Issue 8 Pg. 1948-1960 (08 05 2022) ISSN: 1535-3907 [Electronic] United States
PMID35838755 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • HSP27 Heat-Shock Proteins
  • Sesquiterpenes, Guaiane
  • englerin A
  • p38 Mitogen-Activated Protein Kinases
Topics
  • Apoptosis
  • HSP27 Heat-Shock Proteins (genetics, metabolism, pharmacology)
  • Humans
  • Kidney Neoplasms (drug therapy)
  • Phosphorylation
  • Sesquiterpenes, Guaiane (pharmacology)
  • p38 Mitogen-Activated Protein Kinases (metabolism, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: